ClinicalTrials.gg
Active, not recruitingNCT06958211Updated Nov 9, 2026

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

A Phase 3 interventional study of Ruxolitinib Cream and Vehicle Cream in Hidradenitis Suppurativa, sponsored by Incyte Corporation. Active, not recruiting at 107 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Updated Nov 9, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
573
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.

Enrollment
6th of 12
573 · median 391
Started
2025
with 3 others
Phase 3
6 of 12
1 open now
Registered
9th of 12
by date

Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one is the 6th largest by enrollment, is one of 4 that started in 2025, is one of 6 in phase 3, and was the 9th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hidradenitis Suppurativa by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • Hidradenitis suppurativa
  • skin disease
  • ruxolitinb cream
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of HS for at least 6 months prior to screening visit.
  • Mild to moderate HS (Hurley I or II) with the following at both screening and baseline visits:

    • A total AN count of at least 4, with no draining tunnels AND
    • Affecting at least 2 distinct anatomical areas
  • Agreement to NOT use topical and systemic antibiotics for treatment of HS during the vehicle-controlled period.
  • Agreement to NOT use topical antiseptics, including washes and leave-on products on the areas affected by HS lesions during the vehicle-controlled period and Weeks 16 to 20 of the extension period.
  • Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Body surface areas to be treated exceed 20% BSA at screening or baseline
  • Presence of draining tunnels at screening or baseline.
  • Medical history including current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
  • Laboratory values outside of the protocol-defined criteria.
  • Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.
  • Further exclusion criteria apply.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
573 participants (actual)

Study arms

  • Experimental
    Ruxolitinib 1.5 % Cream

    Participants received ruxolitinib 1.5% cream, applied topically to the affected area as defined in the protocol.

    Drug: Ruxolitinib Cream

  • Placebo comparator
    Vehicle Cream

    Participants received vehicle cream, applied topically to the affected area as defined by the protocol.

    Drug: Vehicle Cream

Interventions

  • Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

  • DrugVehicle Cream

    Matching vehicle cream applied topically to the affected area as a thin film twice daily.

06

What researchers measure

Primary outcomes

  1. Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baseline

    HiSCR75 is defined as at least a 75% reduction from baseline in the total abscess and/or inflammatory nodule (AN) count with no increase from baseline in abscess or draining tunnel count.

    Time frame: Week 16

Secondary outcomes

  1. Proportion of participants with ≥ 1 flare

    Defined as a ≥ 25% increase in AN count with a minimum increase in total AN count of 2 relative to baseline.

    Time frame: Up to 16 weeks

  2. Proportion of participants who achieve HiSCR50

    Defined as a ≥ 50 reduction from baseline in total AN count with no increase from baseline in abscess or draining tunnel count.

    Time frame: Week 16

  3. Proportion of participants who achieve Skin Pain Numeric Rating Scale (NRS)3 among participants with baseline Skin Pain NRS score ≥ 3

    Participants with a Skin Pain score of at least 3 at baseline and who achieve Skin Pain NRS3, defined as at least 3-unit reduction from baseline in the Skin Pain NRS.

    Time frame: Week 16

  4. Treatment-IR Population: Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) from baseline

    Treatment IR-Population defined as participants who had an inadequate response, intolerance, or contraindication to prior topical or systemic medications for HS. HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count with no increase from baseline in abscess or draining tunnel count.

    Time frame: Week 16

  5. Treatment-IR Population: Proportion of participants with ≥ 1 HS flare

    Defined as a ≥ 25% increase in total AN count with a minimum increase in AN count of 2 relative to baseline.

    Time frame: Up to 16 weeks

  6. Treatment-IR Population: Proportion of participants who achieve Skin Pain Numeric Rating Scale (NRS)3 among participants with baseline Skin Pain NRS score ≥ 3

    Participants with a Skin Pain score of at least 3 at baseline and who achieve Skin Pain NRS3, defined as at least 3-unit reduction from baseline in the Skin Pain NRS.

    Time frame: Week 16

  7. Proportion of participants who achieve HiSCR50/75/90/100 at each postbaseline visit

    Defined as a ≥ 50%/75%/90%/100% reduction from baseline in total AN count with no increase from baseline in abscess or draining tunnel count.

    Time frame: Up to 16 weeks

  8. Extension Period: Proportion of participants with ≥ 1 HS flare

    Defined as a ≥ 25% increase in total AN count with a minimum increase in AN count of 2 relative to baseline.

    Time frame: From Week 16 through Week 52

  9. Proportion of participants who achieve abscess and/or inflammatory nodule (AN)75 at each postbaseline visit

    Defined as a ≥ 75% reduction from baseline in total AN count.

    Time frame: Up to 52 weeks

  10. Mean change from baseline in total AN count at each postbaseline visit

    Defined as mean change in total AN count.

    Time frame: Up to 52 weeks

  11. Percentage change from baseline in total AN count at each postbaseline visit

    Defined as percent change from baseline in total AN count.

    Time frame: Up to 52 weeks

  12. Mean change from baseline in abscess count at each postbaseline visit

    Defined as mean change of abscess(es) count relative to baseline.

    Time frame: Up to 52 weeks

  13. Percentage change from baseline in abscess count at each postbaseline visit

    Percent Change from baseline in number of abscess(es).

    Time frame: Up to 52 weeks

  14. Mean change from baseline in inflammatory nodule count at each postbaseline visit

    Defined as mean change of inflammatory nodule count relative to baseline.

    Time frame: Up to 52 weeks

  15. Percentage change from baseline in inflammatory nodule count at each postbaseline visit

    Defined as percent change from baseline in number of inflammatory nodule(s).

    Time frame: Up to 52 weeks

  16. Proportion of participants with presence of draining tunnels at each postbaseline visit

    Participants with presence of draining tunnels.

    Time frame: Up to 52 weeks

  17. Proportion of participants who achieve Skin Pain Numeric Rating Scale (NRS)3 among participants with baseline Skin Pain NRS score ≥ 3 at each postbaseline visit

    Participants with a Skin Pain score of at least 3 at baseline and who achieve Skin Pain NRS3, defined as at least 3-unit reduction from baseline in the Skin Pain NRS.

    Time frame: Up to 52 weeks

  18. Proportion of participants who achieve Itch Numeric Rating Scale (NRS)30 among participants with baseline Itch NRS score ≥ 3 at each postbaseline visit

    Participants with a Itch score of at least 3 at baseline and who achieve Itch NRS30, defined as at least a 30% reduction and at least 1-unit reduction from baseline in the Itch NRS.

    Time frame: Up to 52 weeks

  19. Proportion of participants who achieve Patient Global Impression of Change (PGIC) at each postbaseline visit

    The PGIC is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.

    Time frame: Up to 52 weeks

  20. Proportion of participants who achieve PGIC score 1 or 2 at each postbaseline visit

    The PGIC is based on a 7-point scale and the participant will rate each question from the start of treatment as 1-very much improved, 2-much improved, 3-minimally improved, 4-no change, 5-minimally worse, 6-much worse, and 7-very much worse.

    Time frame: Up to 52 weeks

  21. Patient Global Impression of Severity (PGIS) score at each postbaseline visit

    The PGIS is a single-item, self-reporting measure in which the participant rates the severity of their overall status over the past week based on a 5-point scale: (1) none, (2) mild, (3) moderate, (4) severe, and (5) very severe.

    Time frame: Up to 52 weeks

  22. Change from baseline in PGIS Score at each postbaseline visit

    The PGIS is a single-item, self-reporting measure in which the participant rates the severity of their overall status over the past week based on 5-point scale: (1) none, (2) mild, (3) moderate, (4) severe, and (5) very severe.

    Time frame: Up to 52 weeks

  23. Proportion of participants who achieve status of Dermatology Life Quality Index (DLQ1)4 at each postbaseline visit

    Defined as a ≥ 4-point reduction in DLQI score relative to baseline. The DLQI is a simple, 10-question, validated questionnaire to measure how much a skin problem has affected an adult participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment.

    Time frame: Up to 52 weeks

  24. Proportion of participants who achieve status of Children's Dermatology Life Quality Index (CDLQ1)6 at each postbaseline visit

    Defined as a ≥ 6-point reduction in CDLQI score relative to baseline. The CDLQI is a 10-question, validated questionnaire to measure the impact of skin disease on the lives of children over the previous 7 days.

    Time frame: Up to 52 weeks

  25. Change from baseline in Hidradenitis Suppurativa Quality of Life (HiSQoL) score at each postbaseline visit

    The HiSQoL is a 17-item, HS-specific, health-related, quality-of-life instrument with a 7-day recall period used to assess HS symptoms and the impact of HS problems on quality of life.

    Time frame: Up to 52 weeks

  26. Percent change from baseline in Hidradenitis Suppurativa Quality of Life (HiSQoL) score at each postbaseline visit

    The HiSQoL is a 17-item, HS-specific, health-related, quality-of-life instrument with a 7-day recall period used to assess HS symptoms and the impact of HS problems on quality of life.

    Time frame: Up to 52 weeks

  27. Change from baseline in Hidradenitis Suppurativa Quality of Life - Adolescent (HiSQoL-AA) at each postbaseline visit

    The HiSQoL-AA is a 15-item instrument with a 7-day recall period used to assess HS symptoms and experiences of HS in adolescent.

    Time frame: Up to 52 weeks

  28. Percent change from baseline in Hidradenitis Suppurativa Quality of Life - Adolescent (HiSQoL-AA) at each postbaseline visit

    The HiSQoL-AA is a 15-item instrument with a 7-day recall period used to assess HS symptoms and experiences of HS in adolescent.

    Time frame: Up to 52 weeks

  29. Change from baseline in EuroQol 5-dimension 5-level scale (EQ-5D-5L) score at each postbaseline visit

    The EQ-5D-5L questionnaire is a standardized, validated instrument for use as a measure of health outcome.

    Time frame: Up to 52 weeks

  30. Treatment-IR Population: Change from baseline in total abscess count at each postbaseline visit

    Defined as change from baseline in total abscess count.

    Time frame: Up to 52 weeks

  31. Treatment-IR Population: Percent change from baseline in total abscess count at each postbaseline visit

    Percent Change from baseline in total abscess count.

    Time frame: Up to 52 weeks

  32. Treatment-IR Population: Change from baseline in total inflammatory nodule count at each postbaseline visit

    Defined as change from baseline in total number of inflammatory nodule(s).

    Time frame: Up to 52 weeks

  33. Treatment-IR Population: Percent change from baseline in total inflammatory nodule count at each postbaseline visit

    Defined as percent change from baseline in number of inflammatory nodule(s).

    Time frame: Up to 52 weeks

  34. Treatment-IR Population: Proportion of participants with presence of draining tunnels at each postbaseline visit

    Participants with presence of draining tunnels.

    Time frame: Up to 52 weeks

  35. Number of Treatment Emergent Adverse Events (TEAEs)

    A TEAE or treatment emergent SAE is any AE or SAE either reported for first time or worsening of a pre-existing event after first application of study cream.

    Time frame: Up to 56 weeks

07

Study locations

107 sites
  • Investigative Site US257
    Birmingham, Alabama 35203, United States
  • Investigative Site US218
    Birmingham, Alabama 35244, United States
  • Investigative Site US239
    Montgomery, Alabama 36117, United States
  • Investigative Site US215
    Phoenix, Arizona 85006, United States
  • Investigative Site US261
    Phoenix, Arizona 85037, United States
  • Investigative Site US240
    Tucson, Arizona 85718, United States
  • Investigative Site US262
    Encino, California 91436, United States
  • Investigative Site US222
    Fountain Valley, California 92708, United States
  • Investigative Site US211
    Los Angeles, California 90045, United States
  • Investigative Site US237
    Los Angeles, California 90056, United States
  • Investigative Site US234
    Northridge, California 91325, United States
  • Investigative Site US250
    Santa Ana, California 92706, United States
  • Investigative Site US244
    Castle Rock, Colorado 80109, United States
  • Investigative Site US252
    Cromwell, Connecticut 06416, United States
  • Investigative Site US208
    Boca Raton, Florida 33486, United States
  • Investigative Site US203
    Hialeah, Florida 33012-3618, United States
  • Investigative Site US258
    Jacksonville, Florida 32216, United States
  • Investigative Site US206
    Maitland, Florida 32751, United States
  • Investigative Site US223
    Miami, Florida 33136, United States
  • Investigative Site US241
    Miami, Florida 33147, United States
  • Investigative Site US202
    Miami, Florida 33173, United States
  • Investigative Site US214
    Tampa, Florida 33609, United States
  • Investigative Site US247
    Tampa, Florida 33612, United States
  • Investigative Site US231
    Columbus, Georgia 31904, United States
  • Investigative Site US225
    Sandy Springs, Georgia 30328, United States
  • Investigative Site US207
    Skokie, Illinois 60077, United States
  • Investigative Site US205
    Plainfield, Indiana 46168, United States
  • Investigative Site US264
    Lake Charles, Louisiana 70601, United States
  • Investigative Site US266
    New Orleans, Louisiana 70115, United States
  • Investigative Site US254
    Gambrills, Maryland 21054, United States
  • Investigative Site US201
    Marriottsville, Maryland 21104, United States
  • Investigative Site US253
    Milford, Massachusetts 01757, United States
  • Investigative Site US227
    Needham, Massachusetts 02492, United States
  • Investigative Site US268
    Worcester, Massachusetts 01605, United States
  • Investigative Site US238
    Ann Arbor, Michigan 48103, United States
  • Investigative Site US230
    Auburn Hills, Michigan 48326, United States
  • Investigative Site US251
    St Louis, Missouri 63110-1010, United States
  • Investigative Site US271
    Wildwood, Missouri 63040, United States
  • Investigative Site US212
    Missoula, Montana 59804, United States
  • Investigative Site US216
    Las Vegas, Nevada 89145, United States
  • Investigative Site US235
    Hoboken, New Jersey 07030, United States
  • Investigative Site US217
    Albuquerque, New Mexico 87102, United States
  • Investigative Site US219
    Brooklyn, New York 11203, United States
  • Investigative Site US246
    Elmhurst, New York 11373, United States
  • Investigative Site US269
    Fairport, New York 14450, United States
  • Investigative Site US213
    Kew Gardens, New York 11415, United States
  • Investigative Site US242
    New York, New York 10075, United States
  • Investigative Site US245
    Rochester, New York 14620, United States
  • Investigative Site US259
    Huntersville, North Carolina 28078, United States
  • Investigative Site US263
    Winston-Salem, North Carolina 27104, United States
  • Investigative Site US228
    Cleveland, Ohio 44124, United States
  • Investigative Site US243
    Columbus, Ohio 43213, United States
  • Investigative Site US249
    Columbus, Ohio 43213, United States
  • Investigative Site US204
    Portland, Oregon 97201, United States
  • Investigative Site US226
    Plymouth Meeting, Pennsylvania 19462, United States
  • Investigative Site US256
    Bluffton, South Carolina 29910, United States
  • Investigative Site US267
    Mt. Pleasant, South Carolina 29464, United States
  • Investigative Site US255
    Austin, Texas 78759, United States
  • Investigative Site US260
    Cypress, Texas 77429, United States
  • Investigative Site US270
    Prosper, Texas 75078, United States
  • Investigative Site US232
    Sugar Land, Texas 77479, United States
  • Investigative Site US248
    Arlington, Virginia 22206, United States
  • Investigative Site US209
    Danville, Virginia 24541, United States
  • Investigative Site US229
    Norfolk, Virginia 23502, United States
  • Investigative Site US265
    Seattle, Washington 98105, United States
  • Investigative Site US224
    Spokane, Washington 99202, United States
  • Investigative Site US210
    Milwaukee, Wisconsin 53226, United States
  • Investigative Site BE204
    Brussels, 01070, Belgium
  • Investigative Site BE201
    Ghent, 09000, Belgium
  • Investigative Site BE203
    Ghent, 09000, Belgium
  • Investigative Site BE202
    Leuven, 03000, Belgium
  • Investigative Site BG201
    Sevlievo, 05400, Bulgaria
  • Investigative Site BG202
    Sofia, 01431, Bulgaria
  • Investigative Site BG203
    Sofia, 01592, Bulgaria
  • Investigative Site CA209
    Edmonton, Alberta T5K1X3, Canada
  • Investigative Site CA201
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Investigative Site CA207
    Fredericton, New Brunswick E3B 1G9, Canada
  • Investigative Site CA202
    Hamilton, Ontario L8L 3C3, Canada
  • Investigative Site CA203
    London, Ontario N6H 5L5, Canada
  • Investigative Site CA204
    Markham, Ontario L3P 1X3, Canada
  • Investigative Site CA205
    Mississauga, Ontario L4W 0C2, Canada
  • Investigative Site CA208
    Saskatoon, Saskatchewan S7K 0H6, Canada
  • Investigative Site CA206
    St. John's, A1E 1V4, Canada
  • Investigative Site FR201
    Reims, 51100, France
  • Investigative Site FR203
    Rouen, 76031, France
  • Investigative Site FR204
    Saint-Etienne, 42055, France
  • Investigative Site FR202
    Toulouse, 31059, France
  • Investigative Site DE207
    Bad Bentheim, 48455, Germany
  • Investigative Site DE206
    Göttingen, 37075, Germany
  • Investigative Site DE202
    Hanover, 30159, Germany
  • Investigative Site DE203
    Kiel, 24105, Germany
  • Investigative Site DE205
    Langenau, 89129, Germany
  • Investigative Site DE204
    Merzig, 66663, Germany
  • Investigative Site NL203
    Amsterdam, 1105 AZ, Netherlands
  • Investigative Site NL201
    Rotterdam, 3015 CE, Netherlands
  • Investigative Site PL202
    Lublin, 20-607, Poland
  • Investigative Site LP204
    Poznan, 60-309, Poland
  • Investigative Site PL201
    Rzeszów, 35-055, Poland
  • Investigative Site PL203
    Wroclaw, 54-144, Poland
  • Investigative Site ES205
    Barcelona, 08041, Spain

Showing the first 100 of 107 sites across 9 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Oct 2026, 15 months.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2025
First posted
May 6, 2025
StartActual
Jun 12, 2025
Primary completionActual
Oct 1, 2026
CompletionEst.
Jul 11, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 9, 2026→Oct 1, 2026 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary completion Oct 9, 2026→Oct 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06958211
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
May 6, 2025
Start date
Jun 12, 2025
Primary completion
Oct 1, 2026
Completion
Jul 11, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Incyte Study Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion